Cardiovascular Disease

Adults with depressive symptoms appeared to have increased risk for incident CVD and mortality in economically diverse settings, particularly in urban areas, according to study results published in JAMA Psychiatry.

Icosapent ethyl therapy provides robust cardiovascular benefits in statin-treated adults with type 2 diabetes, with large relative and absolute risk reductions in first and total CV events, study data show.

A smartphone app created by researchers at the New York University College of Dentistry uses artificial intelligence and biomarkers in patients’ blood to assess risk factors and predict COVID-19 severity in patients.

Few patients with primary pulmonary arterial hypertension were treated with exercise rehabilitation in the form of pulmonary or cardiac rehabilitation, according to data scheduled for presentation at the American Thoracic Society International Conference.

Results from a trial published in JAMA demonstrated that medication reduction is feasible in older patients receiving multiple hypertensive treatments for BP control. This was the top story in cardiology last week.

Poorer adults were less likely to be screened for typical CVD risk factors or receive counseling for prevention than patients with higher incomes, regardless of their CV status, researchers reported.

Although patients with rheumatic diseases are at increased risk for cardiovascular events, risk stratification tools and available guidelines to aid rheumatologists in managing these events are lacking, according to data presented at the virtual ACR State-of-the-Art Clinical Symposium.

Medication reduction in older patients treated with multiple antihypertensive medications was noninferior to usual care regarding the control of systolic BP at 12 weeks, according to data from the OPTIMISE trial published in JAMA.

Understanding COVID-19 and SARS-CoV-2 is imperative for the cardiology community, and beyond. To that end, Cardiology Today and Healio convened a panel of experts to discuss the CV implications of COVID-19 and the virus that causes it.

The consumption of one or more servings of sugar-sweetened beverages per day was associated with an increased risk for CVD, stroke and revascularization, according to a study published in the Journal of the American Heart Association.